Dr. Anne Tsao of MD Anderson Cancer Center discusses FDA approval of maintenance therapy and an Annual Meeting update for gemcitabine maintenance therapy. - 100163

Spotlight
Video

Dr. Anne Tsao of MD Anderson Cancer Center discusses FDA approval of maintenance therapy and an Annual Meeting update for gemcitabine maintenance therapy.

videoblog has 63 videos Subscribe Here

Loading........
Description: One of the latest changes in metastatic NSCLC therapy is the inclusion of maintenance therapy after frontline systemic treatment. There are 2 new terms included now in the NCCN guidelines: switch maintenance and continuation maintenance. There are currently 2 FDA approved agents that are switch maintenance: pemetrexed for non-SCC and erlotinib for all NSCLC. This video blog will discuss the clinical trials that led to the FDA approval of maintenance therapy and an ASCO update for gemcitabine maintenance therapy.
Shared By : videoblog
Posted on : 08/25/10
Added : 9 years ago
Category : General